Buy out boom forecast for 2022

Posted 20 January 2021 AM 

The pharma industry is on the cusp of a buy out boom with more than half the respondents in a recent survey of life science companies saying they are focused on pursuing growth through acquisition.

Ben McLaughlin

The Baker Mckenzie Life Sciences Business Evolution Survey of over 250 life sciences respondents from Asia Pacific, North America, Europe and Latin America found 56 per cent were looking at acquisitions for growth, with 52 per cent expecting to use venture capital lending and 51 per cent seeking private equity funding.

To see the whole article, please login